Issue Date: April 10, 2006
GSK, Sirna in respiratory drug pact
In the latest show of faith in the potential of gene-silencing technology, GlaxoSmithKline has teamed up with Sirna Therapeutics to develop RNA interference-based drugs to treat respiratory diseases. GSK will make an initial payment of $12 million comprising cash and investment in Sirna stock. Sirna says it could rake in another $700 million in milestone payments and royalties on potential product sales. Sirna will supply optimized and formulated short interfering RNAs against targets . . .
To view the rest of this content, please log in with your ACS ID.
- Chemical & Engineering News
- ISSN 0009-2347
- Copyright © American Chemical Society